Advertisement
Advertisement
ESLA
Estrella Immunopharma, Inc. Common Stock
0.50
USDSponsored
-0.02
-3.42%
Sep 22, 15:57 UTC -4
Closed
Pre-Market
0.52
+0.01
+2.55%
ESLA Earnings Reports
Positive Surprise Ratio
ESLA beat 2 of 4 last estimates.
50%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.08
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/-38.46%
Estrella Immunopharma, Inc. Common Stock earnings per share and revenue
On --, ESLA reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
FAQ
What were Estrella Immunopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q-- --?
For Q-- --, Estrella Immunopharma, Inc. Common Stock reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to Estrella Immunopharma, Inc. Common Stock's Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Estrella Immunopharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Estrella Immunopharma, Inc. Common Stock's next earnings report?
Based on 3
analysts, Estrella Immunopharma, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.